aTyr Pharma (ATYR) Stock Fair Value Moves Lower As Phase III Funding Risks Loom
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma Files ~$80M At-The-Market Offering To Sell Common Stock Through Jefferies
RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $6
Wells Fargo Maintains Equal-Weight on aTyr Pharma, Raises Price Target to $4
Atyr Pharma: Q3 Earnings Snapshot
aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
aTyr Pharma Q3 EPS $(7.43) Misses $(4.00) Estimate
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
aTyr Pharma Announces One-for-40 Reverse Stock Split
aTyr Pharma Announces 1-For-40 Reverse Stock Split, Effective Oct. 28
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
aTyr Pharma Enters Research Collaboration With Albert Einstein College Of Medicine To Develop And Test ATYR2810, Its Monoclonal Antibody That Targets The Neuropilin-2 Receptor
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Journal Of Biological Chemistry
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Reaches FDA Alignment On Protocol For A Phase 3 Study Of Its Lead Therapeutic Candidate Efzofitimod In Patients With Chronic, Symptomatic Pulmonary Sarcoidosis With Restrictive Lung Disease; Expects To Initiate Study-Related Activities In Q4 2026
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.